Omnes et al. in €10m round for EyeTechCare
Returning backer Omnes Capital has taken part in a €10m series-C round of funding for French medical devices developer EyeTechCare.
The round also included contributions from insurance company and existing EyeTechCare investor Sham, as well as private investor Bernard Chauvin.
The company will use the fresh funds to finalise its EyeMust 2 study and start proceedings to receive regulatory approval from the US Food and Drug Administration. EyeTechCare is planning to launch its products in the US market by the end of 2013.
Omnes and Sham last provided EyeTechCare with a €7.5m round of funding in 2010. Omnes led the round with €4.5m, while Sham invested €3m. EyeTechcare had already raised €1.2m in 2008 from Omnes and CEA-Investissement. Both rounds of funding allowed the business to start commercialising its solutions on the European market at the end of 2012.
Company
EyeTechCare was founded in 2008. It specialises in non-invasive therapeutic medical devices using ultrasound technology, with a focus on glaucoma treatment.
Based in Rillieux-la-Pape, near Lyon, EyeTechCare employs 25 staff.
People
Alexia Perouse represented Omnes on the deal.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








